Desmoglein 2 antibody fusion proteins for drug delivery
US11458208B2 · kind B2 · utility
0Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2017 |
| Grant date | Oct 4, 2022 |
| Priority date | — |
| Expiry date | Mar 26, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to antibody fusion proteins. Particularly, the invention relates to antibody fusion proteins for intra-cellular and intra-nucleus drugs delivery. The fusion protein of the invention can be used as a peptide penetration system that specifically binds to various targets for the delivery of effector peptides across a biological barrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.